A Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of AZD8630, Administered Once Daily via Inhalation, for 2 Weeks, in Adults with Asthma on Medium-to-high Dose Inhaled Corticosteroids and Long-acting Beta-agonists

2024-514213-35-00 Protocol D6830C00004 Human pharmacology (Phase I) - Other Ended

Start 20 Jan 2025 · End 27 Jun 2025 · Status Ended · 1 EU/EEA countries · 5 sites · Protocol D6830C00004

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - Other
Status Ended
Participants planned 24
Countries 1
Sites 5

Asthma

Key facts

Sponsor
AstraZeneca AB
Participant type
Patients
Age range
18-64 years, 65+ years
Gender
Male and Female
Therapeutic area
Diseases [C] - Respiratory Tract Diseases [C08]
Trial duration
20 Jan 2025 → 27 Jun 2025
Decision date (initial)
2024-10-17
Transition trial
No
Low-intervention
No
Rare-disease indication
No
Vulnerable population
Yes

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

Asthma

VersionLevelCodeTermSystem organ class
20.0 PT 10003553 Asthma 100000004855

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

AstraZeneca AB

Sponsor organisation
AstraZeneca AB
Address
-
City
Sodertalje
Postcode
151 85
Country
Sweden

Scientific contact point

Organisation
AstraZeneca AB
Contact name
AstraZeneca Clinical Study Information Center

Public contact point

Organisation
AstraZeneca AB
Contact name
AstraZeneca Clinical Study Information Center

Locations

1 EU/EEA country · 5 investigational sites

By country

CountryMS statusPlanned subjectsSites
Germany Ended 24 5
Rest of world 0

Investigational sites

Germany

5 sites · Ended
IKF Pneumologie GmbH & Co. KG
2605:Institut für klinische Forschung Pneumologie, Haifa-Allee 24, Bretzenheim, Mainz
IKF Pneumologie GmbH & Co. KG
2602: Pulmonology, 2nd Floor, Schaumainkai 101-103, Frankfurt Am Main
Velocity Clinical Research Germany GmbH
2603: Pulmonology, Klaus-Groth-Strasse 2-4, 22926, Ahrensburg
Studienpraxis Berlin-Brandenburg Cornelia Seelbinder Und Lennart Schaper GbR
2601: Pulmonology, Torstrasse 117, Mitte, Berlin
Velocity Clinical Research Germany GmbH
Pulmunology, Sandstrasse 18, Innenstadt, Luebeck

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
Germany 2025-01-20 2025-06-27 2025-01-28 2025-05-20

Application history

4 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2024-07-30 Germany Acceptable
2024-10-15
2024-10-17
2 SUBSTANTIAL MODIFICATION SM-1 2024-10-23 Germany Acceptable 2024-11-15
3 SUBSTANTIAL MODIFICATION SM-3 2025-02-14 Germany Acceptable 2025-02-28
4 SUBSTANTIAL MODIFICATION SM-4 2025-03-14 Germany Acceptable 2025-04-01